enoximone sulfoxide: sulfoxide metabolite of MDL 17043; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 158474 |
| SCHEMBL ID | 10922402 |
| MeSH ID | M0122433 |
| Synonym |
|---|
| enoximone sulfoxide |
| mdl-19,438 |
| mdl 17043 sulfoxide |
| 83982-78-9 |
| 2h-imidazol-2-one, 1,3-dihydro-4-methyl-5-(4-(methylsulfinyl)benzoyl)-, (2s-(1(r*(r*)),2r*))- |
| SCHEMBL10922402 |
| EX-A7368 |
| DTXSID301004246 |
| (2-hydroxy-4-methyl-1h-imidazol-5-yl)[4-(methanesulfinyl)phenyl]methanone |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The average steady-state plasma concentrations for enoximone were 115 +/- 40 ng/mL and 190 +/- 78 ng/mL for 50 mg every 8 hours and 100 mg every 8 hours dosage regimens, respectively." | ( Disposition kinetics of orally administered enoximone in patients with moderate to severe heart failure. Kates, RE; Lebsack, C; Mead, RH; Ruder, MA; Smith, N; Winkle, RA, 1991) | 0.28 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.44) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||